The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also ...

About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.

GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk: London, UK Tuesday, May 19, 2026, 12:00 Hrs [IST] GSK plc announced tha ...

Hospital Authority says patient, who had history of chronic obstructive pulmonary disease and high cholesterol, died ...

Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of the Viz ...

If you have chronic obstructive pulmonary disease (COPD)—an umbrella term for several lung diseases, including emphysema, ...

The UK's coastal ambient air quality, often perceived as inherently healthpromoting, contrasts with the poor health outcomes ...

Lupin received US FDA tentative approval for Revefenacin Inhalation Solution (175 mcg/3 mL), bioequivalent to Yupelri, ...

Pairing vulnerable, low-income patients with asthma coaches can improve outcomes and may also reduce costs associated with ...

Among hospitalized adults with acute exacerbation of COPD, pegtarazimod improved oxygen utilization and inflammatory ...

Preliminary inspection found abnormality in screw-on connector at end of catheter used during heart operation on elderly man ...

Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc.